← Back to headlines
UBS Boosts Bristol-Myers Squibb Price Target Ahead of Milvexian Data
UBS has increased its price target for Bristol-Myers Squibb (BMY) as the market anticipates upcoming data for its drug Milvexian.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippines No Longer Southeast Asia's Worst for Fuel Price Hikes, Economic Pain Persists
just now
Bohol Governor Orders Austerity for May Fiestas Amid Economic Pressures
just now
Philippines Police Boost Market Patrols Amid Price Freeze
just now